Reasons to Invest
Introduction
I have dedicated my life to helping others break free from nicotine addiction. With 21 years of experience in the quit-smoking laser therapy industry, we aim to obtain FDA approval for Freedom Laser’s patented home use medical-grade device and disrupt the $2 billion annual U.S. smoking cessation industry, changing millions of lives in the process.
Inventor of the Freedom Quit Smoking Laser
Two decades ago, Entrepreneur Craig Nabat, a former pack-and-a-half-a-day smoker, embarked on a transformative journey to break free from nicotine addiction. His turning point came through a 30-minute low-level laser therapy procedure in Canada—an innovative and pain-free approach recognized globally as the modern form of acupuncture addiction treatment. This groundbreaking procedure empowered Nabat to conquer his smoking habit for good.
Since that pivotal moment, Craig Nabat's dream has been to free millions worldwide from the deadly and highly addictive clutches of nicotine. Years of dedicated research and collaborative development with a team of expert engineers culminated in creating the nation's first home-use quit smoking laser device— an embodiment of the Company's commitment to providing accessible, effective, non-invasive, and drug-free solution to nicotine addiction.
Our mission is clear: to obtain the first United States FDA approval for the Company's patented low-level laser device, designed to alleviate nicotine addiction withdrawal symptoms. With this milestone, we aim to fulfill our vivid vision—to
Freeing the World from Nicotine Addiction™.
Your support in our equity crowdfunding campaign may not only propel this groundbreaking technology into homes worldwide but also contribute to a global movement dedicated to breaking the chains of nicotine addiction. Join us in making a profound impact on the lives of millions and ushering in an era where freedom from nicotine addiction is a reality for all.
Success to Date
- 21 years of clinical experience using low-level laser therapy to treat 10,000+ Freedom Laser smokers and vaping clients
- Awarded utility patents in the United States and China
- Performed animal study using low-level lasers on mice at the University of Buffalo, resulting in an immediate physical response
- Conducted a successful 28-subject IRB-approved pilot study, validating the Freedom device significantly reduced smoking consumption
- Finalized laser device design, user manual, and retail packaging
- Revised the protocol for an FDA clinical research trial based on IRB pilot study findings to confirm the Freedom Quit Smoking Laser temporarily alleviates nicotine withdrawal symptoms
- Conducted first FDA pre-submission meeting to present the clinical trial protocol
- Notable past invention and marketing success story: known for inventing the FDA Cleared iRestore Hair Growth System device and Hair Care Line Brand, generating tens of millions in annual sales. View more about this product here.
The Problem
The Solution
Market
History
Marketing & Branding
With a registered symbol mark for the Freedom trademark, Freedom Laser Inc. has been championing the efficacy of low-level laser technology in nationwide media for more than two decades under the Freedom brand. The intuitive and distinctive trademark is synonymous with Freedom from addiction and pain, reducing the need for significant investment in market education to communicate the nature of the promoted product.
Frequently Asked Questions
Addiction Treatment Centers: Establish long-term partnerships and sell through the nation’s 16,000+ addiction clinics.
Medical Providers: Physicians can prescribe the device to smoking or vaping patients to treat nicotine addiction Pharmaceutical Retailers: Establish pharmaceutical retails such as CVS.com and Walgreens.com.
Direct-to-Consumer over-the-counter (OTC): Ability to purchase our product via our e-commerce website without a prescription.
Distribute through the Department of Veterans Affairs (VA) nationwide network of hospitals and clinics.
Distribute through the United States Armed Forces. This includes:
- United States Army
- United States Marine Corps
- United States Navy
- United States Air Force
- United States Space Force
- United States Coast Guard
Market the device to employees who have health savings accounts (HSAs) and flexible spending accounts (FSAs), these accounts are intended to cover qualified medical expenses.
Secure Insurance Coverage: Strive to obtain insurance coverage, although it is not essential to the overall distribution strategy.
Over the first two years, we plan to prioritize the following activities: FDA correspondence meetings, device inventory production, safety testing, conducting FDA clinical research, obtaining FDA approval, developing an e-commerce website, and establishing distribution channels through addiction treatment centers and medical device distributors.
IRB-Approved Study Protocol
∙ 28 Subjects
∙ Mixed demographics age 21-65
∙ 25-day study duration
∙ Two 12-minute daily sessions for the first three days
∙ One 12-minute daily session for the remaining 22 days of the pilot study duration
Results: The Freedom Quit Smoking Laser active user group experienced a 50% decrease in cigarette smoking consumption compared to the placebo group.
Here are the key aspects of the trial:
FDA Clinical Trial Protocol
∙ Number of test subjects: 60
∙ Demographics: Participants aged 21-65, with an equal gender distribution (50% male and 50% female)
∙ Study duration: 30 days, conducted as a double-blind study
∙ Increase treatment duration from 12 minutes to 15 minutes
∙ Daily sessions: Two 15-minute sessions per day for the study trial duration
∙ Laser power output: Increase safely by 50% compared to the pilot study
Expected FDA Trial Results
∙ Validation of the indication for use claim: The device aims to aid in reducing the symptoms of nicotine withdrawal
∙ Significant reduction in cigarette consumption with the possibility of total cessation
This comprehensive protocol and the expected outcomes demonstrate the effectiveness and safety of the Freedom Quit Smoking Laser in helping individuals reduce their cigarette consumption and manage nicotine withdrawal symptoms.
Freedom Laser, Inc. is proactively developing connections with strategic investors with well-established business relationships with physicians, insurance companies, hospitals, medical device distributors, corporations engaged in smoking cessation programs, corporate wellness programs/initiatives, and organizers of employee health fairs.
Important Information
Freedom Laser, Inc. (“the Company”) is leveraging the low-level laser therapy technology and know-how from Freedom Laser Therapy, Inc. (“Freedom Laser Therapy”), which was originally established in 2003. Freedom Laser Therapy and Freedom Laser, LLC have more than two decades of experience using quit smoking laser therapy in a clinical setting. The Company intends to use their experience and accomplishments to assist it in succeeding. Since 2019, Freedom Laser Therapy’s quit smoking laser therapy clinic has operated under the company name Freedom Laser, LLC.
The Company does not own Freedom Laser Therapy or Freedom Laser, LLC, and has no financial ties to either entity.
*Our goal is to be the nation's only FDA approved home use quit smoking laser device.
Use of Proceeds
If the offering's maximum amount of $275,000 is raised:
| Use | Value | % of Proceeds |
|---|---|---|
| Clinical Trials and Research | $90,000 | 32.7% |
| Financial and Legal | $71,525 | 26.0% |
| Production, Inventory, and Safety Testing | $55,000 | 20.0% |
| Operational and Administrative Costs | $20,000 | 7.3% |
| Regulatory and Compliance | $20,000 | 7.3% |
| Marketing and Public Relations | $5,000 | 1.8% |
| Intermediary fees | $13,475 | 4.9% |
Terms
This number includes all funds raised by the Company in this round on Netcapital. This is an offering of Common Stock, under registration exemption 4(a)(6), in Freedom Laser, Inc.. This offering must reach its target of at least $10,000 by its offering deadline of January 10, 2025 at 11:59pm ET. If this offering does not reach its target by the offering deadline, then your money will be refunded.
If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:
Financials
These financial statements have been reviewed by an independent Certified Public Accountant.
SEC Filings
The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.
We’re also required to share links to each of the SEC filings related to this offering with investors.
Understand the Risks
Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.
Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
More Info
Updates
- Apr 10, 2024We're thrilled to announce that with the...
- Apr 5, 2024Freedom Laser, Inc. already exceeded the first...
Ask a Question
Proofread your comment before submitting: once it's posted, you can’t edit or delete it. Investors are advised to review our Discussion Board Policy before submitting a comment. For the fastest help with the web site, email help@netcapital.com instead of commenting.
Looking to raise capital?
We can help turn your friends, family and customers into investors.
Interested in more investment opportunities?
Browse all offerings currently available.